|
ALL ALS unites researchers, people living with ALS, families, government, industry, and nonprofit organizations to drive progress toward effective treatments and, ultimately, a future without ALS.
Through this large observational study, the consortium is collecting clinical data, biological samples, and digital health measurements from thousands of participants living with ALS, those at genetic risk, and healthy volunteers across the U.S. to advance research and improve quality of life. |
|
- People living with ALS can participate completely remotely.
- There are more than 30 clinical ALL ALS sites across the U.S. and Puerto Rico.
- ALL ALS is collaborating with other research studies, including Target ALS, the ALS Natural History Study, the CDC National ALS Registry, and ALL FTD.
- ALL ALS is designed specifically to allow people to participate in both ALL ALS and experimental drug trials at the same time.
- Collected data and samples will be made available to approved-researchers for innovative ALS research, while ensuring participant confidentiality is maintained through strict data-sharing agreements.
You can fill out an interest form on the ALL ALS website or email [email protected] with questions.
About ALL ALS
|
The Access for All in ALS (ALL ALS) Research Consortium is a nationwide initiative funded by the NIH to make ALS research more accessible to everyone impacted by the disease. By collecting and sharing data and samples from people living with ALS, those at genetic risk, and healthy volunteers, ALL ALS aims to advance ALS research and accelerate the development of new treatments.
|
|
